Bio-Rad Laboratories earnings date
Want to see BIO full AI Analyst Report?
Bio-Rad Laboratories (BIO) Q3 2026 Earnings Report
BIO Q3 2026 EPS Results
- Actual EPS
- $2.65
- Consensus EPS
- $2.23
- Beat/Miss
- Beat by +$0.42
- One Year Ago EPS
- $2.26
BIO Q3 2026 Revenue Results
- Actual Revenue
- $656.40M
- Expected Revenue
- $649.94M
- Beat/Miss
- Beat by +$6.46M
- YoY Revenue Growth
- +0.52%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Bio-Rad Laboratories's next earnings date is estimated for February 18, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call conveyed cautious optimism. Bio-Rad highlighted a return to modest currency-neutral revenue growth, improving non-GAAP margins, strong ddPCR instrumentation, Diagnostics growth, product launches and ongoing restructuring and innovation initiatives. However, these positives were offset by declining total Life Science revenue, weak academic and government funding, China pricing pressure, logistics disruption, an expected fourth-quarter margin decline, negative-to-flat full-year revenue guidance and GAAP losses driven by restructuring and impairment charges. Management expects positive but not fully normalized growth in 2027.
Bio-Rad reaffirmed full year '26 currency-neutral revenue growth between minus 3% and plus 0.5%, with full year growth expected to be approximately at the midpoint of this range; Life Science segments currency-neutral revenue growth is expected to be between minus 3% and minus 1%, and Clinical Diagnostics segment's currency-neutral revenue growth between minus 3% and plus 1%. Q4 revenue is expected to ramp up 5% to 6% on a reported basis, full year non-GAAP gross margin is expected in the upper half of the guidance range of between 53% and 54%, and full year non-GAAP operating margin in the upper half of the guidance range of between 10% and 12%; Q4 SG&A is expected to be flat to Q3, R&D to step up $3 million sequentially, and depreciation and amortization to be approximately $40 million. Full year 2026 free cash flow is expected to be in the range of approximately $290 million to $340 million. Management is focused on driving towards positive growth rate in '27 and driving further margin expansion in '27; it estimated the National Healthcare Security Administration guidelines' revenue impact in the middle single-digit millions of dollars in 2027, expects logistics disruption to continue into 2027, and expects $30 million, $35 million in restructuring savings, with full realization starting in '28.
- Return to Currency-Neutral Revenue GrowthThird-quarter revenue was approximately $656 million, up 0.5% on a reported basis and 0.7% on a currency-neutral basis versus the prior year. This was Bio-Rad's first quarter of currency-neutral growth in 2026.
- Improved Non-GAAP Gross MarginNon-GAAP gross margin increased to 54.5% from 53.5% in the prior-year quarter and improved sequentially from 53.9% in the second quarter.
- Clinical Diagnostics Returned to GrowthClinical Diagnostics revenue increased 2.7% on a reported basis and 2.8% on a currency-neutral basis to approximately $402 million, driven by timing of orders in Quality Systems and Diabetes products. Quality Controls remained the company's largest Diagnostics franchise and continued to show global strength, while Diabetes also showed broad-based strength during 2026.
- Life Science Growth Excluding Process ChromatographyLife Science currency-neutral revenue excluding Process Chromatography increased 2.5% year-over-year, representing the third consecutive quarter of sequential improvement in the growth rate.
- Strong ddPCR Instrument PerformanceThe ddPCR portfolio delivered 7% currency-neutral growth, with instrument revenue increasing more than 20% year-over-year for the third consecutive quarter. Performance was supported by conversions from traditional qPCR, competitive wins, the expanded portfolio, the assay library and a simplified workflow.
- Encouraging Biopharma Demand TrendsManagement reported signs of improving customer activity in biopharma. The recovery remains gradual, but activity has expanded from later-stage large pharmaceutical and biotechnology customers toward discovery-related work.
- Process Chromatography Sequential ImprovementProcess Chromatography revenue improved sequentially throughout 2026, and management expects full-year 2026 revenue to improve year-over-year despite an expected sequential decline in the fourth quarter.
- Return to Growth in China During the QuarterChina returned to growth in the third quarter, largely driven by orders shifted from the second quarter and a favorable prior-year comparison. Quality Controls continued to be strong in the region.
- AI Operational and Product InitiativesBio-Rad is applying AI to processes intended to improve productivity, decision-making and execution, while also incorporating AI into products to enhance their capabilities and customer value. Management said AI-related transitions from in-silico modeling to wet-lab work could support more productive testing and greater use of reagents and products.
- ChemiDoc Pro Launch AcceleratedBio-Rad launched the ChemiDoc Pro western blot imaging system during the quarter. The launch was accelerated by approximately two quarters through product-development prioritization and execution improvements. Its analytical algorithm was developed using AI trained on thousands of western blot images.
- Expanded Foresight Pro PortfolioThe company expanded its Foresight Pro pre-packed chromatography column portfolio to include Nuvia resins, broadening the available customer formats through closer collaboration among product development, marketing and field application teams.
- Improved Non-GAAP Operating ResultsThird-quarter non-GAAP operating margin increased to 12.8% from 11.8% in the prior-year quarter and improved sequentially from 12.5%. Non-GAAP net income rose to $72 million, or $2.65 diluted EPS, from $61 million, or $2.26 diluted EPS.
- Restructuring Savings Plan Remains on TrackManagement said the restructuring plan announced in the second quarter is proceeding. The expected $30 million to $35 million of savings remains intact, with actions taking hold during the latter part of 2026 and throughout 2027 and full realization expected starting in 2028.
- Reaffirmed Cash Flow and Margin OutlookBio-Rad reaffirmed its 2026 free cash flow estimate of approximately $290 million to $340 million, having generated $210 million through nine months. Full-year non-GAAP gross margin and operating margin are expected in the upper halves of their respective guidance ranges of 53% to 54% and 10% to 12%.
- Continued Investment in Innovation and Supply ChainThe company continues to invest in innovation capability, supply-chain efficiency, procurement, inventory management and manufacturing-footprint optimization. These initiatives were described as components of efforts to improve gross margin and build a more efficient operating model.
- Board and Stakeholder EngagementThe Board is evaluating candidates to add broader operational experience in life science tools and diagnostics. Management also said its dialogue with Elliott Management remains active and productive and that the parties are broadly aligned on objectives.
- Balanced Capital Allocation FrameworkBio-Rad continues to invest in the business and innovation, remains opportunistic rather than systematic with share repurchases, and is considering acquisitions with approximately $100 million to $500 million of revenue in the Diagnostics or life science tools markets. The company is not seeking transformative deals.
BIO Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 18, 2027 | 2026 (Q4) | 2.83- | 2.51 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | 2.232.65 | 2.26 | 17.26% (+0.39) | |
| Aug 04, 2026 | 2026 (Q2) | 1.752.62 | 2.61 | 0.38% (+0.01) | |
| Apr 30, 2026 | 2026 (Q1) | 1.971.89 | 2.54 | -25.59% (-0.65) | |
| Feb 12, 2026 | 2025 (Q4) | 2.712.51 | 2.9 | -13.45% (-0.39) | |
| Oct 29, 2025 | 2025 (Q3) | 1.952.26 | 2.01 | 12.44% (+0.25) | |
| Jul 31, 2025 | 2025 (Q2) | 1.732.61 | 3.11 | -16.08% (-0.50) | |
| May 01, 2025 | 2025 (Q1) | 1.812.54 | 2.29 | 10.92% (+0.25) | |
| Feb 13, 2025 | 2024 (Q4) | 2.872.90 | 3.1 | -6.45% (-0.20) | |
| Oct 30, 2024 | 2024 (Q3) | 1.162.01 | 2.33 | -13.73% (-0.32) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


